Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trine Bertelsen

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of the American Academy of Dermatology|April 26, 2026
Comparative Two-Year Drug Survival of Bimekizumab and Brodalumab in Second-Line Treatment of PsoriasisChristopher Willy Schwarz, Nikolai Loft, Lars Erik Bryld, et al.
JAMA Dermatology|January 7, 2026
Drug Survival of Biologics in Bionaive and Bioexperienced Patients With PsoriasisChristopher Willy Schwarz, Nikolai Loft, Lars Erik Bryld, et al.
Journal of the American Academy of Dermatology|February 5, 2023
Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort studyMia-Louise Nielsen, David Thein, Mads Kirchheiner Rasmussen, et al.
JAMA Dermatology|August 17, 2022
Multivariable Predictive Models to Identify the Optimal Biologic Therapy for Treatment of Patients With Psoriasis at the Individual LevelMia-Louise Nielsen, Troels Christian Petersen, Julia-Tatjana Maul, et al.
Ugeskrift for Laeger|April 2, 2025
[Hidradenitis suppurativa]Hans Christian Ring, Peter Theut Riis, Mads Rasmussen, et al.
Acta Dermato-Venereologica|March 3, 2025
Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort StudyJohan Sieborg, Julia-Tatjana Maul, Jashin J Wu, et al.
International Journal of Molecular Sciences|June 19, 2024
Secukinumab and Dead Sea Climatotherapy Impact Resolved Psoriasis Skin Differently Potentially Affecting Disease MemoryThomas Emmanuel, Borislav Ignatov, Trine Bertelsen, et al.
Ugeskrift for Laeger|November 21, 2025
[Vaccination of individuals undergoing immunosuppressive therapy]Zitta Barrella Harboe, Peter Henrik Andersen, Peter Asdahl, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of the American Academy of Dermatology|April 26, 2026
Comparative Two-Year Drug Survival of Bimekizumab and Brodalumab in Second-Line Treatment of PsoriasisChristopher Willy Schwarz, Nikolai Loft, Lars Erik Bryld, et al.
JAMA Dermatology|January 7, 2026
Drug Survival of Biologics in Bionaive and Bioexperienced Patients With PsoriasisChristopher Willy Schwarz, Nikolai Loft, Lars Erik Bryld, et al.
Journal of the American Academy of Dermatology|February 5, 2023
Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort studyMia-Louise Nielsen, David Thein, Mads Kirchheiner Rasmussen, et al.
JAMA Dermatology|August 17, 2022
Multivariable Predictive Models to Identify the Optimal Biologic Therapy for Treatment of Patients With Psoriasis at the Individual LevelMia-Louise Nielsen, Troels Christian Petersen, Julia-Tatjana Maul, et al.
Ugeskrift for Laeger|April 2, 2025
[Hidradenitis suppurativa]Hans Christian Ring, Peter Theut Riis, Mads Rasmussen, et al.
Acta Dermato-Venereologica|March 3, 2025
Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort StudyJohan Sieborg, Julia-Tatjana Maul, Jashin J Wu, et al.
International Journal of Molecular Sciences|June 19, 2024
Secukinumab and Dead Sea Climatotherapy Impact Resolved Psoriasis Skin Differently Potentially Affecting Disease MemoryThomas Emmanuel, Borislav Ignatov, Trine Bertelsen, et al.
Ugeskrift for Laeger|November 21, 2025
[Vaccination of individuals undergoing immunosuppressive therapy]Zitta Barrella Harboe, Peter Henrik Andersen, Peter Asdahl, et al.
Pageof 4